SVRA
Price:
$6.37
Market Cap:
$1.30B
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Industry
Biotechnology
IPO Date
2017-04-28
Stock Exchange
NASDAQ
Ticker
SVRA
According to Savara Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -12.02. This represents a change of 98.88% compared to the average of -6.04 of the last 4 quarters.
The mean historical PE Ratio of Savara Inc. over the last ten years is -5.03. The current -12.02 PE Ratio has changed 23.80% with respect to the historical average. Over the past ten years (40 quarters), SVRA's PE Ratio was at its highest in in the March 2016 quarter at -0.50. The PE Ratio was at its lowest in in the December 2017 quarter at -16.35.
Average
-5.03
Median
-3.98
Minimum
-14.20
Maximum
-0.51
Discovering the peaks and valleys of Savara Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 426.55%
Maximum Annual PE Ratio = -0.51
Minimum Annual Increase = -55.30%
Minimum Annual PE Ratio = -14.20
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -6.35 | -55.30% |
| 2023 | -14.20 | 128.70% |
| 2022 | -6.21 | 60.78% |
| 2021 | -3.86 | 180.83% |
| 2020 | -1.37 | -40.07% |
| 2019 | -2.29 | -44.02% |
| 2018 | -4.10 | -53.04% |
| 2017 | -8.73 | 225.25% |
| 2016 | -2.68 | 426.55% |
| 2015 | -0.51 | -4.53% |
The current PE Ratio of Savara Inc. (SVRA) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
-8.92
5-year avg
-6.40
10-year avg
-5.03
Savara Inc.’s PE Ratio is greater than Tyra Biosciences, Inc. (-12.44), greater than Rezolute, Inc. (-13.00), less than ProKidney Corp. (-4.64), less than Kura Oncology, Inc. (-4.84), greater than Nanobiotix S.A. (-12.92), less than EyePoint Pharmaceuticals, Inc. (-5.70), greater than GH Research PLC (-23.21), less than Bicara Therapeutics Inc. Common Stock (-9.97), less than Geron Corporation (-10.59), less than Tango Therapeutics, Inc. (-7.52),
| Company | PE Ratio | Market cap |
|---|---|---|
| -12.44 | $1.18B | |
| -13.00 | $899.46M | |
| -4.64 | $723.22M | |
| -4.84 | $1.04B | |
| -12.92 | $1.04B | |
| -5.70 | $1.15B | |
| -23.21 | $952.15M | |
| -9.97 | $1.03B | |
| -10.59 | $810.71M | |
| -7.52 | $1.09B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Savara Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Savara Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Savara Inc.'s PE Ratio?
How is the PE Ratio calculated for Savara Inc. (SVRA)?
What is the highest PE Ratio for Savara Inc. (SVRA)?
What is the 3-year average PE Ratio for Savara Inc. (SVRA)?
What is the 5-year average PE Ratio for Savara Inc. (SVRA)?
How does the current PE Ratio for Savara Inc. (SVRA) compare to its historical average?